Looking back at Cohort #3 and relevant timelines, it was a more than 3 months after completion of dosing that we learned that one of those patients had self reported an improvement of their microperimetry vision.
In my opinion PYC would've been super excited about this and would have felt an urge to shout it out from the rooftops however when it comes to clinical studies, proper protocol must always be adhered to. The self reported improvement would have needed to be confirmed by follow up assessments, (RP11 natural history study), at both 4 weeks and 8 weeks after dosing. Once confirmed by these follow up assessments, that's when PYC would have been in a position to let us know, which it did.
So in regard to Cohort #4, (dose increased from 50mg to 75mg), we now know it is safe which is a HUGE tick. This has me thinking, will Cohort #4 with increased dosing...
1) provide greater improvement, I.E will more borderline dormant cells reactivate and therefore we achieve a stronger efficacy insight/signal?
2) become more durable, does a bigger dose equate to a longer lasting effect?
In my head we are probably going to have to be patient for about another month, maybe a tad more, for proper protocol which would include follow up assessments to be completed. After that, PYC should be able announce if any patients have gained measurable visual improvements and by how much.
Personally I feel quite optimistic and eagerly await for this information to 'drop'.
PYC Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)